Champions Oncology, Inc. (CSBR) stock
CSBRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 11, 2026Score 10/30245% above fair value
$4.68−0.03 (-0.53%)
Close on Nov 16, 2026Market cap $65.14MP/E –Yield –
Champions Oncology price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Champions Oncology's price to book ratio was 17.1× on Nov 11, 2026, against 25.7× a year earlier. Over the last 5 years it ranged from 6.1× to 221.1×, with a median of 18.6×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 17.1× | −5.9 |
| 2025 | Dec 31, 2025 | 23.0× | −149.4 |
| 2024 | Dec 31, 2024 | 172.4× | +135.9 |
| 2023 | Nov 30, 2023 | 36.5× | +29.8 |
| 2022 | Dec 30, 2022 | 6.7× | −7.3 |
| 2021 | Dec 31, 2021 | 14.0× | −6.9 |
| 2020 | Dec 31, 2020 | 20.9× | −24.9 |
| 2019 | Dec 31, 2019 | 45.8× | +0.8 |
| 2018 | Dec 31, 2018 | 45.0× | −69.3 |
| 2017 | Dec 29, 2017 | 114.3× | +105.6 |
| 2016 | Dec 30, 2016 | 8.7× | +1.1 |
| 2015 | Dec 31, 2015 | 7.6× | −89.9 |
| 2014 | Nov 28, 2014 | 97.5× | – |
See a number that looks wrong?